SUN-2016

NCT01245959 📎

Regimen

Experimental
Induction TPF (docetaxel 60 mg/m² d1 + cisplatin 60 mg/m² d1 + 5-FU 600 mg/m²/d d1-5) ×3 cycles, then concurrent CCRT (cisplatin 100 mg/m² q3w ×3 + IMRT)
Control
Concurrent CCRT alone (cisplatin 100 mg/m² q3w ×3 + IMRT)

Population

Locoregionally advanced NPC (stage III-IVB, M0) confirmed by IMRT era staging, multicentre mainland China

Key finding

First large-scale IMRT-era Chinese multicentre phase 3 RCT demonstrating that adding TPF induction chemotherapy to CCRT significantly improves failure-free survival in locoregionally advanced NPC. Led entirely by Sun Yat-sen University Cancer Center (PI: Ma J / Sun Y team), this trial repositioned TPF induction as a viable strategy in IMRT-based practice. Driven mainly by better distant metastasis control, consistent with the micrometastasis hypothesis. The 3-year OS result numerically favoured induction but was not powered for this endpoint.

Source: PMID 27686945

Timeline

    Guideline citations

    • NCCN NPC (p.42)